Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23394983 | 0.77 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL7899491 | 0.70 | CTSA (0.36) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL5399850 | 0.68 | CTSA (0.39) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL423317 | 0.68 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL11312598 | 0.67 | KDM4E (0.45) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL5399854 | 0.65 | CTSA (0.36) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL11279635 | 0.65 | CTSA (0.36) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL9701526 | 0.65 | CTSA (0.36) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL4905870 | 0.64 | CTSA (0.43) | CTSAACHEALDH1A1KDM4EPOLB | |
| SCHEMBL4212873 | 0.64 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096116-B1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MAN CO LTD (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2096116-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | MAN2B2, MAN2A1, MAN2B1 | CTSA 1804/4885ACHE 941/4885ALDH1A1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.